PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, will initiate a clinical trial of ColoAd1, a systemically available oncolytic vaccine, to compare the effectiveness of direct intra-tumoral injection with intravenous injection in patients with non-metastatic colorectal cancer. The study aims to better understand the mechanism of action (MOA) of this highly potent, broad-spectrum, anti-cancer therapeutic capable of destroying tumour cells at minute concentrations.
The study is the second clinical trial of ColoAd1 currently underway and is expected to recruit up to 16 patients at two sites in Spain to compare direct intra-tumoral injection with intravenous injection. Tumour samples from the patients will then be examined for evidence of viral replication, viral spread, tumour necrosis and anti-tumoral immune responses.
See the full article and other news here
Posted on Monday 24th June 2013